📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Towards Repairing Degenerated Intervertebral Discs using pH-Responsive Microgels

Lead Research Organisation: University of Manchester
Department Name: Materials

Abstract

Degeneration of the intervertebral disc (DIVD) is a process that results in generation of interconnected voids within IVDs. The voids result in a loss of disc height and chronic low back pain. DIVD has a major adverse effect on society. The estimated cost of DIVD due to lost productivity in the US in 2004 was $USD 40 billion. Current spinal therapy for DIVD involves major surgical intervention with protracted recovery times. There is an urgent need for a minimally invasive DIVD treatment that restores disc height. In our 12 month feasibility study (GR/S75819/01) it was shown that injection of a pH-responsive microgel dispersion into a degenerated IVD could restore the disc height to normal values under biomechanical loads. Microgels are pH-responsive polymer colloid particles that expand when the particle charge increases. They can be triggered to form physical gels using pH within degenerated IVDs. This continuation proposal seeks to investigate the principles underpinning IVD load support by physically gelled microgels and extend the work to study covalently-linked microgel particle gels. This study seeks to deliver a set of design rules that will enable future clinical development of an injectable microgel repair system for DIVD.
 
Description An efficient method for constructing doubly crosslinked microgels was established and used to demonstrate mechanical property restoration for degenerated intervertebral discs.
Exploitation Route A spin out was created to take the materials to the clinic
Sectors Pharmaceuticals and Medical Biotechnology

 
Description UMIP
Amount £147,000 (GBP)
Funding ID POP 
Organisation UMIP Premier Fund Ltd 
Sector Private
Country United Kingdom
Start  
 
Description UMIP
Amount £147,000 (GBP)
Funding ID POP 
Organisation University of Manchester 
Department Intellectual Property
Sector Academic/University
Country United Kingdom
Start  
 
Company Name Gelmetix 
Description Gelmetix has developed a non-surgical treatment for lower back pain that utilises injectable bio-materials that are specifically designed to replicate the bio-mechanical properties of a healthy inter-vertebral disc. 
Year Established 2012 
Impact The company has attracted more than £1 M of inward investment.
Website http://www.gelexir-healthcare.co.uk